Skip to search formSkip to main contentSkip to account menu

armodafinil

Known as: (-)-2-[(R)-(diphenylmethyl)sulfinyl]acetamide, 2-((R)-(diphenylmethyl)sulfinyl)acetamide, (-)-2-((R)-(Diphenylmethyl)sulfinyl)acetamide 
The R-enantiomer of the racemic synthetic agent modafinil with central nervous system (CNS) stimulant and wakefulness-promoting activities. Although… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
ABSTRACT We present the case of a 21-year-old woman in whom Stevens-Johnson syndrome (SJS) developed after initiation of… 
2013
2013
Parkinson’s disease with dementia (PDD) and dementia with Lewy bodies (DLB) share several disturbances of attention, including… 
2012
2012
The wakefulness‐promoting medication armodafinil (R‐modafinil) is being studied as an adjunctive treatment for patients with… 
Review
2010
Review
2010
Behavioral measures, eg, exercise and improved sleep hygiene, can enhance sleep quality and combat insomnia and excessive… 
Review
2009
Review
2009
Excessive sleepiness (ES) is responsible for significant morbidity and mortality due to its association with cardiovascular… 
2008
2008
Armodafinil, the (R)-enantiomer of modafinil, is a medication used to treat the excessive sleepiness associated with narcolepsy… 
2008
2008
Armodafinil is a unique psychostimulant recently approved by the US Food and Drug Administration for the treatment of narcolepsy…